# A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

> **NCT03131206** · PHASE1,PHASE2 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 5 (actual)

## Conditions studied

- ALK-positive Non-small Cell Lung Cancer (NSCLC)
- RET-positive Non-small Cell Lung Cancer (NSCLC)
- RET-positive Thyroid Cancer

## Interventions

- **DRUG:** Alectinib

## Key facts

- **NCT ID:** NCT03131206
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-19
- **Primary completion:** 2018-11-08
- **Final completion:** 2019-04-08
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Study closed due to slow accrual and lack of efficacy.
- **Last updated:** 2021-09-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03131206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03131206, "A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03131206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*